Tumor-induced immune escape mechanisms and translational immunotherapeutic strategies

Tumor-induced immune evasion is a critical mechanism that promotes resistance to anticancer therapies and facilitates cancer progression. Notwithstanding the emergence of immunotherapies, especially immune checkpoint inhibitors (ICIs) and adoptive cell therapies, several cancers show resistance against such therapeutic interventions by adopting various methods of immune evasion. These include alterations to the tumor microenvironment (TME), infiltration of immunosuppressive cells, overexpression of inhibitory checkpoint molecules, and modified antigen presentation. This study provides a comprehensive assessment of the cellular and molecular principles behind immune evasion, as well as novel and established strategies for its prevention. The mechanisms, clinical implications, and limitations of significant therapeutic modalities, including checkpoint blockade, CAR-T cell therapy, cancer vaccines, and oncolytic virotherapy, are addressed. Particular emphasis is placed on combinatorial approaches, TME reprogramming, and next-generation targets like LAG-3, TIM-3, and TIGIT. The research examines the potential of predictive biomarkers, including PD-L1, Tumor Mutational Burden (TMB), Microsatellite Instability (MSI), and the microbiome, to guide personalized immunotherapy. Overcoming resistance and achieving enduring responses requires the integration of immunological insights with high-throughput molecular profiling and adaptive clinical trial design as the subject develops. The efficacy of immunotherapies across many cancer types may be enhanced by adopting a systems-level perspectives on tumor-immune interactions. Ultimately, restoring effective antitumor immunity with new, customized therapies is a crucial advancement in current oncology.